Table 3:
Treatment emergent Adverse events for cabozantinib and weekly paclitaxel
| Site | No of events for Cabozantinib Arm | No. of events for Weekly Paciltaxel | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Gr 2 | Gr 3 | Gr 4 | Gr 5 | Gr 2 | Gr 3 | Gr 4 | Gr 5 | ||
| Thrombocytopenia | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Neutropenia | 10 | 2 | 0 | 0 | 14 | 4 | 0 | 0 | |
| Anemia | 5 | 3 | 1 | 0 | 12 | 0 | 0 | 0 | |
| Gastrointestinal | 20 | 14 | 1 | 0 | 10 | 2 | 0 | 0 | |
| Endocrine | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Metabolism/nutrition | 10 | 8 | 2 | 0 | 7 | 3 | 0 | 0 | |
| Musculoskeletal/Connective Tissue | 8 | 1 | 0 | 0 | 4 | 0 | 0 | 0 | |
| Nervous system | 7 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | |
| Renal/urinary | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Respiratory/Thoracic/Mediastinal | 12 | 3 | 0 | 0 | 8 | 1 | 0 | 0 | |
| Skin/subcutaneous | 12 | 2 | 0 | 0 | 20 | 0 | 0 | 0 | |
| Vascular Disorders | 10 | 12 | 0 | 0 | 6 | 4 | 1 | 0 | |